A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia
B. G. Wells, J. A. Cold, P. A. Marken, C. S. Brown, C. C. Chu, R. P. Johnson, C. S. Nasdahl, M. A. Ayubi, D. H. Knott, Kristopher Arheart
Background: Although propranolol has been documented to be useful in treatment of neuroleptic-induced akathisia, preliminary anecdotal reports on the efficacy of nadolol in treatment of this condition are contradictory. Method: To evaluate the efficacy of nadolol in treatment of this condition, a double-blind, placebo-controlled trial was conducted in 20 psychiatric inpatients. Patients with akathisia of at least moderate severity were randomly assigned to receive nadolol 40 to 80 mg/day or placebo. Patients were rated daily for 4 days, then every other day for 15 days by means of the Extrapyramidal Symptom Rating Scale. Results: No significant differences were found between or within groups in subjective restlessness scores. In objective akathisia scores, there were no significant differences between groups; however, beginning at Day 9, both groups showed significant improvement compared with Day 1. There was no difference between groups in number of responders. Conclusions: The authors' data do not support the efficacy of nadolol in the treatment of neuroleptic-induced akathisia and do not provide support for a peripheral site of action for β-blockers in treatment of this condition.
Journal of Clinical Psychiatry
Nadolol
Psychomotor Agitation
Antipsychotic Agents
Wells, B. G., Cold, J. A., Marken, P. A., Brown, C. S., Chu, C. C., Johnson, R. P., ... Arheart, K. (1991). A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. Journal of Clinical Psychiatry, 52(6), 255-260.
A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. / Wells, B. G.; Cold, J. A.; Marken, P. A.; Brown, C. S.; Chu, C. C.; Johnson, R. P.; Nasdahl, C. S.; Ayubi, M. A.; Knott, D. H.; Arheart, Kristopher.
In: Journal of Clinical Psychiatry, Vol. 52, No. 6, 01.01.1991, p. 255-260.
Wells, BG, Cold, JA, Marken, PA, Brown, CS, Chu, CC, Johnson, RP, Nasdahl, CS, Ayubi, MA, Knott, DH & Arheart, K 1991, 'A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia', Journal of Clinical Psychiatry, vol. 52, no. 6, pp. 255-260.
Wells BG, Cold JA, Marken PA, Brown CS, Chu CC, Johnson RP et al. A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. Journal of Clinical Psychiatry. 1991 Jan 1;52(6):255-260.
Wells, B. G. ; Cold, J. A. ; Marken, P. A. ; Brown, C. S. ; Chu, C. C. ; Johnson, R. P. ; Nasdahl, C. S. ; Ayubi, M. A. ; Knott, D. H. ; Arheart, Kristopher. / A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. In: Journal of Clinical Psychiatry. 1991 ; Vol. 52, No. 6. pp. 255-260.
@article{ef4ebdab355e46bdb365af15d178ee87,
title = "A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia",
abstract = "Background: Although propranolol has been documented to be useful in treatment of neuroleptic-induced akathisia, preliminary anecdotal reports on the efficacy of nadolol in treatment of this condition are contradictory. Method: To evaluate the efficacy of nadolol in treatment of this condition, a double-blind, placebo-controlled trial was conducted in 20 psychiatric inpatients. Patients with akathisia of at least moderate severity were randomly assigned to receive nadolol 40 to 80 mg/day or placebo. Patients were rated daily for 4 days, then every other day for 15 days by means of the Extrapyramidal Symptom Rating Scale. Results: No significant differences were found between or within groups in subjective restlessness scores. In objective akathisia scores, there were no significant differences between groups; however, beginning at Day 9, both groups showed significant improvement compared with Day 1. There was no difference between groups in number of responders. Conclusions: The authors' data do not support the efficacy of nadolol in the treatment of neuroleptic-induced akathisia and do not provide support for a peripheral site of action for β-blockers in treatment of this condition.",
author = "Wells, {B. G.} and Cold, {J. A.} and Marken, {P. A.} and Brown, {C. S.} and Chu, {C. C.} and Johnson, {R. P.} and Nasdahl, {C. S.} and Ayubi, {M. A.} and Knott, {D. H.} and Kristopher Arheart",
journal = "Journal of Clinical Psychiatry",
publisher = "Physicians Postgraduate Press Inc.",
T1 - A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia
AU - Wells, B. G.
AU - Cold, J. A.
AU - Marken, P. A.
AU - Brown, C. S.
AU - Chu, C. C.
AU - Johnson, R. P.
AU - Nasdahl, C. S.
AU - Ayubi, M. A.
AU - Knott, D. H.
AU - Arheart, Kristopher
N2 - Background: Although propranolol has been documented to be useful in treatment of neuroleptic-induced akathisia, preliminary anecdotal reports on the efficacy of nadolol in treatment of this condition are contradictory. Method: To evaluate the efficacy of nadolol in treatment of this condition, a double-blind, placebo-controlled trial was conducted in 20 psychiatric inpatients. Patients with akathisia of at least moderate severity were randomly assigned to receive nadolol 40 to 80 mg/day or placebo. Patients were rated daily for 4 days, then every other day for 15 days by means of the Extrapyramidal Symptom Rating Scale. Results: No significant differences were found between or within groups in subjective restlessness scores. In objective akathisia scores, there were no significant differences between groups; however, beginning at Day 9, both groups showed significant improvement compared with Day 1. There was no difference between groups in number of responders. Conclusions: The authors' data do not support the efficacy of nadolol in the treatment of neuroleptic-induced akathisia and do not provide support for a peripheral site of action for β-blockers in treatment of this condition.
AB - Background: Although propranolol has been documented to be useful in treatment of neuroleptic-induced akathisia, preliminary anecdotal reports on the efficacy of nadolol in treatment of this condition are contradictory. Method: To evaluate the efficacy of nadolol in treatment of this condition, a double-blind, placebo-controlled trial was conducted in 20 psychiatric inpatients. Patients with akathisia of at least moderate severity were randomly assigned to receive nadolol 40 to 80 mg/day or placebo. Patients were rated daily for 4 days, then every other day for 15 days by means of the Extrapyramidal Symptom Rating Scale. Results: No significant differences were found between or within groups in subjective restlessness scores. In objective akathisia scores, there were no significant differences between groups; however, beginning at Day 9, both groups showed significant improvement compared with Day 1. There was no difference between groups in number of responders. Conclusions: The authors' data do not support the efficacy of nadolol in the treatment of neuroleptic-induced akathisia and do not provide support for a peripheral site of action for β-blockers in treatment of this condition.
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry